Ardent Health Partners, Inc. (NYSE:ARDT) just released its latest full-year results and things are looking bullish. It was overall a positive result, with revenues beating expectations by 2.1% to hit US$6.0b. Ardent Health Partners also reported a statutory profit of US$1.58, which was an impressive 33% above what the analysts had forecast. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

View our latest analysis for Ardent Health Partners NYSE:ARDT Earnings and Revenue Growth March 1st 2025

Taking into account the latest results, the current consensus from Ardent Health Partners' ten analysts is for revenues of US$6.32b in 2025. This would reflect a modest 5.9% increase on its revenue over the past 12 months. Per-share earnings are expected to surge 29% to US$1.90. In the lead-up to this report, the analysts had been modelling revenues of US$6.30b and earnings per share (EPS) of US$1.93 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

It will come as no surprise then, to learn that the consensus price target is largely unchanged at US$21.60. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Ardent Health Partners at US$25.00 per share, while the most bearish prices it at US$17.00. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Ardent Health Partners shareholders.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of Ardent Health Partners'historical trends, as the 5.9% annualised revenue growth to the end of 2025 is roughly in line with the 6.2% annual growth over the past three years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 7.1% per year. So although Ardent Health Partners is expected to maintain its revenue growth rate, it's forecast to grow slower than the wider industry.

Story Continues

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Ardent Health Partners' revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that in mind, we wouldn't be too quick to come to a conclusion on Ardent Health Partners. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Ardent Health Partners analysts - going out to 2027, and you can see them free on our platform here.

You can also see whether Ardent Health Partners is carrying too much debt, and whether its balance sheet is healthy, for free  on our platform here.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments